Table 2 Summary of Other KRASG12C inhibitors [35, 56, 59,60,61, 64, 66,67,68,69, 73,74,75,76]
From: The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Agent | Pharmaceutical Company | Clinical Trial (CT) | ORR of CT | DCR of CT | TRAEs |
|---|---|---|---|---|---|
LY3537982 | Eli Lilly and Company | Phase I (NCT04956640) | 60% | 80% | Diarrhea, constipation, fatigue, peripheral edema, nausea, neutropenia |
GDC-6036 | Genentech | Phase I (NCT04449874) | 53.4% | – | Rash, diarrhea, nausea, vomiting, dry skin, and paronychia |
D-1553 | InvestisBio | Phase I/II (NCT04585035) | 40.5% | 91.9% | Elevated AST/ALT increased, diarrhea, hypertension, hypokalemia, increased total or conjugated bilirubin, hypothyroidism, and nausea |
HBI-2438 | Huyabio International | Phase I (NCT05485974) | – | – | – |
JDQ443 | Novartis | Phase Ib/II (NCT04699188) | 41.7% 54.5% (RP2D of 200 mg BID) | – | Fatigue, edema, diarrhea, nausea, vomiting, and peripheral neuropathy |
JAB-21822 | Jacobio Pharma | Phase I/II (NCT05009329) | 70% (400 & 800Â mg QD groups) | 100% (400 & 800Â mg QD groups) | Anemia, total bilirubin increase, and proteinuria |
HS-10370 | Jiangsu Hansoh Pharmaceutical company | Phase I/II (NCT05367778) | – | – | – |
IBI-351 (GFH925) | Innovent Biologics Inc | Phase I/II (NCT05005234) | 61.2% 53.3% (RP2D of 600Â mg BID) | 92.5% 96.7% (RP2D of 600Â mg BID) | Anemia, white blood cell count decreased, ALT increases, and pruritus |
BI-1823911 | Boehringer Ingelheim | Phase I (NCT04973163) | – | – | – |
JNJ-74699157 | Johnson & Johnson | Phase I (NCT04006301) | – | – | Increased blood creatinine phosphokinase (grade 3–4) |